Directors’ Dealings

MemberShares 31/12/2022Options 31/12/2022
Dr. Gerd Zettlmeissl, Chairman of the Supervisory Board00
Antoinette Hiebeler-Hasner, Deputy Chair of the Supervisory Board00
Dr. Anthony Man00
Dr. Keith Manchester(until 18 May 2022)00
Dr. Frank Mathias20,1970
Ronald Scott00
Total Supervisory Board20,1970
Dr. Selwyn Ho, CEO (since July 25, 2022)29,000190,000
Prof. Dr. Dolores J. Schendel, CEO (until July 24, 2022), CSO (since July 25,2022)3846,296157,500
Dr. Kai Pinkernell, Member of the Executive Management Board (until 31 March 2021)073,438
Axel Sven Malkomes, Member of the Executive Management Board (until 31 March 2022)095,000
Total Executive Management Board875,296
  1. Dr. Manchester is a partner and Head of Life Sciences QVT Financial LP New York, USA. According to the latest voting rights announcement dated 8 June 2018, the funds managed by QVT hold 1,072,879 shares in Medigene AG.
  2. Prof. Schendel indirectly holds 846,296 Medigene shares in her capacity as Managing Director of DJSMontana Holding GmbH, which can be allocated to Prof. Schendel directly.